Tadayoshi Okimoto
Research Subjects
Tadayoshi Okimoto has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Kazunari Murakami
Department of Gastroenterology Faculty of Medicine Oita University Oita Japan
4 shared publications - Masaaki Kodama
Department of Gastroenterology Faculty of Medicine Oita University Oita Japan
4 shared publications Kazuhiro Mizukami
3 shared publications- Kazuhiro Mizukami
Department of Gastroenterology, Faculty of Medicine, Oita University, Oita, Japan
3 shared publications Kazuhisa Okamoto
3 shared publicationsKazunari Murakami
3 shared publications
Latest Publications
- Open Access
- 17 January 2025
- Published by S. Karger AG in Digestive Diseases
- Vol. 43 (2) , 158-169
Comparison of Genetic Mutations of Gastric Cancer Diagnosed before or after Helicobacter pylori Eradication and between Differentiated and Undifferentiated Types Using Next-Generation Sequencing
Introduction: Genetic abnormalities specific to post-Helicobacter pylori eradication gastric cancer (GC), especially those associated with undifferentiated post-eradication GC, are unknown. We conducted next-generation sequencing of GC diagnosed either before or after eradication to investigate the carcinogenesis of post-eradication GC. Methods: Five cases of post-eradication differentiated GC [HP(–)-D group], five cases of H. pylori-positive differentiated GC [HP(+)-D group], four cases of post-eradication undifferentiated GC [HP(–)-U group], and six cases of H. pylori-positive undifferentiated GC [HP(+)-U group] underwent analysis. DNA was extracted from tumor samples, and non-tumor samples of all subjects. Next-generation target sequencing was conducted using the Ion AmpliSeq Library Kit 2.0 with the Ion AmpliSeq Cancer Hotspot Panel v2. Next-generation targeted sequencing results of the cancer part were subtracted from the results of the non-cancer part. Results: The HP(–)-D group displayed significantly fewer SNPs in hotspot than the other groups (p < 0.01). Definitive DNA mutations were identified by sequencing of cancerous and non-cancerous tissues. 5 of 20 patients had specific somatic mutations, with different TP53 mutations in the HP(+)-D and HP(–)-U groups, CTNNB1 mutations in the HP(+)-U group, and ATM mutations in the HP(+)-U group, but no mutations in the HP(–)-D group. Conclusion: Several definite genetic mutations involved in GC were observed. Mutations were less frequent in post-eradication differentiated GC. However, because of small number of cases analyzed to identify carcinogenic differences, further analysis with a large number of cases and with strictly grading GC samples is needed.
- 17 January 2025
- Published by S. Karger AG in Digestive Diseases
- Vol. 43 (2) , 158-169
Open AccessComparison of Genetic Mutations of Gastric Cancer Diagnosed before or after Helicobacter pylori Eradication and between Differentiated and Undifferentiated Types Using Next-Generation Sequencing
Introduction: Genetic abnormalities specific to post-Helicobacter pylori eradication gastric cancer (GC), especially those associated with undifferentiated post-eradication GC, are unknown. We conducted next-generation sequencing of GC diagnosed either before or after eradication to investigate the carcinogenesis of post-eradication GC. Methods: Five cases of post-eradication differentiated GC [HP(–)-D group], five cases of H. pylori-positive differentiated GC [HP(+)-D group], four cases of post-eradication undifferentiated GC [HP(–)-U group], and six cases of H. pylori-positive undifferentiated GC [HP(+)-U group] underwent analysis. DNA was extracted from tumor samples, and non-tumor samples of all subjects. Next-generation target sequencing was conducted using the Ion AmpliSeq Library Kit 2.0 with the Ion AmpliSeq Cancer Hotspot Panel v2. Next-generation targeted sequencing results of the cancer part were subtracted from the results of the non-cancer part. Results: The HP(–)-D group displayed significantly fewer SNPs in hotspot than the other groups (p < 0.01). Definitive DNA mutations were identified by sequencing of cancerous and non-cancerous tissues. 5 of 20 patients had specific somatic mutations, with different TP53 mutations in the HP(+)-D and HP(–)-U groups, CTNNB1 mutations in the HP(+)-U group, and ATM mutations in the HP(+)-U group, but no mutations in the HP(–)-D group. Conclusion: Several definite genetic mutations involved in GC were observed. Mutations were less frequent in post-eradication differentiated GC. However, because of small number of cases analyzed to identify carcinogenic differences, further analysis with a large number of cases and with strictly grading GC samples is needed.
- Open Access
- 12 October 2023
- Published by Wiley in Helicobacter
- Vol. 29 (1) , e13028
Antimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020
Background: Antimicrobial therapy is necessary to eradicate Helicobacter pylori infection. The emergence of antimicrobial‐resistant bacteria poses a threat to continued treatment with antimicrobial agents. For those who prescribe antimicrobial therapy, it is necessary to constantly monitor the emergence of antimicrobial‐resistant bacteria.Method: H. pylori clinical isolates were collected in Japan from August 2018 to December 2020 for antimicrobial susceptibility testing. The agar dilution method was used for the determination of the minimum inhibitory concentration (MIC) of clarithromycin (CLR), amoxicillin (AMX), metronidazole (MNZ), and sitafloxacin (STX).Results: MICs for 938 H. pylori isolates were examined. The primary resistance rates of H. pylori clinical isolates for CLR, AMX, MNZ, and STX in Japan were 35.5%, 2.7%, 4.2%, and 27.6%, respectively. The primary resistance rates for CLR, AMX, and MNZ were significantly higher than those of the 2002–2005 isolates. The resistance rate for CLR was significantly higher in females (males: 30.7%, females: 41.5%, p < 0.001) and higher in the ≤29 years age group (54.8%) than in the other age groups, although there were no significant differences (p = 0.104). The MNZ resistance rate was significantly higher in the ≤29 years age group than in the other age groups (p = 0.004). The resistance rate for STX increased with age, but a significant difference was only seen between the 30–49 years age group and the ≥70 years age group (p < 0.001), and the resistance rate was significantly higher in strains isolated in the Kyushu region than in the other regions (p < 0.001).Conclusions: The primary resistance rates for CLR, AMX, and MNZ of H. pylori clinical isolates in Japan were higher than those of the 2002–2005 isolates. Continuous surveillance is needed to monitor the trends in antimicrobial‐resistant H. pylori.
- 12 October 2023
- Published by Wiley in Helicobacter
- Vol. 29 (1) , e13028
Open AccessAntimicrobial‐resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018–2020
Background: Antimicrobial therapy is necessary to eradicate Helicobacter pylori infection. The emergence of antimicrobial‐resistant bacteria poses a threat to continued treatment with antimicrobial agents. For those who prescribe antimicrobial therapy, it is necessary to constantly monitor the emergence of antimicrobial‐resistant bacteria.Method: H. pylori clinical isolates were collected in Japan from August 2018 to December 2020 for antimicrobial susceptibility testing. The agar dilution method was used for the determination of the minimum inhibitory concentration (MIC) of clarithromycin (CLR), amoxicillin (AMX), metronidazole (MNZ), and sitafloxacin (STX).Results: MICs for 938 H. pylori isolates were examined. The primary resistance rates of H. pylori clinical isolates for CLR, AMX, MNZ, and STX in Japan were 35.5%, 2.7%, 4.2%, and 27.6%, respectively. The primary resistance rates for CLR, AMX, and MNZ were significantly higher than those of the 2002–2005 isolates. The resistance rate for CLR was significantly higher in females (males: 30.7%, females: 41.5%, p < 0.001) and higher in the ≤29 years age group (54.8%) than in the other age groups, although there were no significant differences (p = 0.104). The MNZ resistance rate was significantly higher in the ≤29 years age group than in the other age groups (p = 0.004). The resistance rate for STX increased with age, but a significant difference was only seen between the 30–49 years age group and the ≥70 years age group (p < 0.001), and the resistance rate was significantly higher in strains isolated in the Kyushu region than in the other regions (p < 0.001).Conclusions: The primary resistance rates for CLR, AMX, and MNZ of H. pylori clinical isolates in Japan were higher than those of the 2002–2005 isolates. Continuous surveillance is needed to monitor the trends in antimicrobial‐resistant H. pylori.
- 18 April 2023
- Published by S. Karger AG in Digestion
- Vol. 104 (5) , 409-414
Efficacy of the Castor Oil-Filled Capsule Method as Preparation for Colon Capsule Endoscopy
Background: Colon capsule endoscopy (CCE) is useful as an alternative examination for patients in whom colonoscopy is difficult. The Japanese Association for Capsule Endoscopy has published a recommended regimen for CCE using castor oil, which is becoming a standard examination method for CCE in Japan. However, castor oil has an unpleasant flavor. Therefore, patient acceptance is not good. Objectives: The aims were to develop a castor oil-filled capsule and evaluate its feasibility and patient acceptance in a retrospective, comparative study. Method: A dissolution study of pig-derived gelatin capsules filled with castor oil was performed using artificial gastric juice. The CCE excretion rates within battery lifetime, CCE examination times, endoscopic colonic cleansing levels, and patient acceptability between CCE boosters with a castor oil-filled capsule and without castor oil were retrospectively compared using medical information, clinical data, and endoscopic findings at Takada Chuo Hospital from September 2016 to August 2019. Results: The castor oil-filled capsules were completely disintegrated at approximately 1–3 min in artificial gastric juice. Bowel preparation with oil-filled capsules and without castor oil was performed in 27 and 24 patients, respectively. CCE excretion rates within battery life were 100% and 91.7% (p = 0.217), small bowel transit times were 115 min and 143 min (p = 0.046), colon transit times were 168 min and 148 min (p = 0.733), and adequate colonic cleansing rates were 85.2% and 86.3% (p = 1.000) in patients using bowel preparation with and without oil-filled capsules, respectively. Regarding acceptance, the taste was not problematic in 85.2%, and tolerability for the next CCE was 96.3%. Conclusions: CCE using a castor oil-filled capsule method achieved high examination performance and sufficient patient tolerability.
- 18 April 2023
- Published by S. Karger AG in Digestion
- Vol. 104 (5) , 409-414
Efficacy of the Castor Oil-Filled Capsule Method as Preparation for Colon Capsule Endoscopy
Background: Colon capsule endoscopy (CCE) is useful as an alternative examination for patients in whom colonoscopy is difficult. The Japanese Association for Capsule Endoscopy has published a recommended regimen for CCE using castor oil, which is becoming a standard examination method for CCE in Japan. However, castor oil has an unpleasant flavor. Therefore, patient acceptance is not good. Objectives: The aims were to develop a castor oil-filled capsule and evaluate its feasibility and patient acceptance in a retrospective, comparative study. Method: A dissolution study of pig-derived gelatin capsules filled with castor oil was performed using artificial gastric juice. The CCE excretion rates within battery lifetime, CCE examination times, endoscopic colonic cleansing levels, and patient acceptability between CCE boosters with a castor oil-filled capsule and without castor oil were retrospectively compared using medical information, clinical data, and endoscopic findings at Takada Chuo Hospital from September 2016 to August 2019. Results: The castor oil-filled capsules were completely disintegrated at approximately 1–3 min in artificial gastric juice. Bowel preparation with oil-filled capsules and without castor oil was performed in 27 and 24 patients, respectively. CCE excretion rates within battery life were 100% and 91.7% (p = 0.217), small bowel transit times were 115 min and 143 min (p = 0.046), colon transit times were 168 min and 148 min (p = 0.733), and adequate colonic cleansing rates were 85.2% and 86.3% (p = 1.000) in patients using bowel preparation with and without oil-filled capsules, respectively. Regarding acceptance, the taste was not problematic in 85.2%, and tolerability for the next CCE was 96.3%. Conclusions: CCE using a castor oil-filled capsule method achieved high examination performance and sufficient patient tolerability.
- 3 March 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (8) , 2210-2216
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long‐term prospective follow‐up study
Background and Aim: Improvement of atrophic gastritis and intestinal metaplasia (IM) is considered to reduce the gastric cancer risk, but whether it can be achieved by H. pylori eradication (HPE) remains controversial. To evaluate the effect of HPE, we observed the gastric mucosa for up to17 years after HPE and sex differences in gastric mucosa.Methods: In total, 172 patients (94 males, 78 females) with HPE were enrolled. Annual histological evaluations were performed for up to 17 years. The grades of mononuclear cells, neutrophils, atrophy, IM in the antrum and corpus were evaluated using the updated Sydney system.Results: Relative to the pre‐HPE period, atrophy had improved significantly 1 year after HPE in the antrum (1.50 ± 0.75 vs. 1.21 ± 1.25, P < 0.01) and corpus (0.59 ± 0.75 vs. 0.18 ± 0.52, P < 0.05). IM showed no significant change during 17 years after HPE at either biopsy site. Atrophy scores did not differ significantly between males and females. IM scores were significantly higher in males than in females before eradication (antrum, 0.67 ± 0.94 vs. 0.44 ± 0.77, P = 0.003, corpus, 0.20 ± 0.62 vs. 0.047 ± 0.21, P = 0.0027) and at most observation timepoints.Conclusions: During 17 years after HPE, atrophy, but not IM, improved significantly at the greater curvatures of the antrum and corpus. IM was significantly more severe in males than in females. Careful follow‐up after HPE based on sex differences in gastric mucosal characteristics is important.
- 3 March 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (8) , 2210-2216
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long‐term prospective follow‐up study
Background and Aim: Improvement of atrophic gastritis and intestinal metaplasia (IM) is considered to reduce the gastric cancer risk, but whether it can be achieved by H. pylori eradication (HPE) remains controversial. To evaluate the effect of HPE, we observed the gastric mucosa for up to17 years after HPE and sex differences in gastric mucosa.Methods: In total, 172 patients (94 males, 78 females) with HPE were enrolled. Annual histological evaluations were performed for up to 17 years. The grades of mononuclear cells, neutrophils, atrophy, IM in the antrum and corpus were evaluated using the updated Sydney system.Results: Relative to the pre‐HPE period, atrophy had improved significantly 1 year after HPE in the antrum (1.50 ± 0.75 vs. 1.21 ± 1.25, P < 0.01) and corpus (0.59 ± 0.75 vs. 0.18 ± 0.52, P < 0.05). IM showed no significant change during 17 years after HPE at either biopsy site. Atrophy scores did not differ significantly between males and females. IM scores were significantly higher in males than in females before eradication (antrum, 0.67 ± 0.94 vs. 0.44 ± 0.77, P = 0.003, corpus, 0.20 ± 0.62 vs. 0.047 ± 0.21, P = 0.0027) and at most observation timepoints.Conclusions: During 17 years after HPE, atrophy, but not IM, improved significantly at the greater curvatures of the antrum and corpus. IM was significantly more severe in males than in females. Careful follow‐up after HPE based on sex differences in gastric mucosal characteristics is important.
- 7 March 2018
- Published by S. Karger AG in Digestion
- Vol. 97 (4) , 288-297
Endoscopic and Immunohistochemical Characteristics of Gastric Cancer with versus without Helicobacter Pylori Eradication
Background/Aims: The rate of gastric cancer (GC) after Helicobacter pylori eradication has gradually increased; therefore, we investigate the clinicopathological features of GC following eradication in comparison with those of GC with H. pylori infection. Methods: This study included 50 subjects with GC after eradication (GCE) and 151 patients with GC with H. pylori infection (GCI). Clinicopathological factors were assessed. The manifestation of GC was further evaluated using immunohistochemical analysis and in situ hybridization. Results: Macroscopic analysis revealed a significantly higher ratio of depressed type /elevated type in the GCE compared with the GCI (30/19 vs. 61/77, p = 0.041). The gastric phenotype was more common in the GCE compared with the GCI, and the proportion of CDX2-positive cases was lower in the GCE (8 out of 18; 44.4%) compared with the GCI (18 out of 19; 94.7%; p = 0.00082). Ki-67 labeling index was significantly lower in the GCE (32.03 ± 22.15) compared with the GCI (79.20 ± 14.87, p < 0.0001). No patient in the GCE showed evidence of Epstein-Barr virus infection. Conclusion: The clinicopathological characteristics of GC following H. pylori eradication differ from those of GC in patients with H. pylori infection in terms of morphology, mucin phenotype, and proliferation rate.
- 7 March 2018
- Published by S. Karger AG in Digestion
- Vol. 97 (4) , 288-297
Endoscopic and Immunohistochemical Characteristics of Gastric Cancer with versus without Helicobacter Pylori Eradication
Background/Aims: The rate of gastric cancer (GC) after Helicobacter pylori eradication has gradually increased; therefore, we investigate the clinicopathological features of GC following eradication in comparison with those of GC with H. pylori infection. Methods: This study included 50 subjects with GC after eradication (GCE) and 151 patients with GC with H. pylori infection (GCI). Clinicopathological factors were assessed. The manifestation of GC was further evaluated using immunohistochemical analysis and in situ hybridization. Results: Macroscopic analysis revealed a significantly higher ratio of depressed type /elevated type in the GCE compared with the GCI (30/19 vs. 61/77, p = 0.041). The gastric phenotype was more common in the GCE compared with the GCI, and the proportion of CDX2-positive cases was lower in the GCE (8 out of 18; 44.4%) compared with the GCI (18 out of 19; 94.7%; p = 0.00082). Ki-67 labeling index was significantly lower in the GCE (32.03 ± 22.15) compared with the GCI (79.20 ± 14.87, p < 0.0001). No patient in the GCE showed evidence of Epstein-Barr virus infection. Conclusion: The clinicopathological characteristics of GC following H. pylori eradication differ from those of GC in patients with H. pylori infection in terms of morphology, mucin phenotype, and proliferation rate.
- Open Access
- 10 February 2012
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 44 (S 02) , E246-E247
A case of Good syndrome with refractory gastrointestinal ulcers
A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication). On the patient’s admission, laboratory examination revealed severe hypogammaglobulinemia, absence of peripheral B cells, CD4+ T-cell lymphopenia, and inverted CD4 /CD8+ T-cell ratio. Pathogenic bacteria, cytomegalovirus, and human immunodeficiency virus tests were negative. From these results and her medical history, the patient was diagnosed with Good syndrome with PRCA, and was treated with intravenous immune globulin (IVIG) every 2 weeks. At 2 months later, her immune globulin level had increased to normal. Previously upper and lower gastrointestinal endoscopy had shown an ulcer at the greater curvature ([Fig. 1 a]), and similar multiple ulcers at the ileocecum and the terminal ileum on admission ([Fig. 1 c]). Histopathological analysis of the biopsy specimens from these lesions showed a lack of plasma cells in the lamina propria, epithelial apoptosis, and increased intraepithelial lymphocytes (IELs) ([Fig. 2]). Similarly, 2 months after initiation of IVIG treatment, these lesions were markedly improved ([Fig. 1 b, d]), and the epithelial apoptosis and IELs had disappeared. Good syndrome is defined as thymoma with adult-onset immunodeficiency, and is characterized by hypogammaglobulinemia, low or absent B-cells, CD4+ T-cell lymphopenia, and inverted CD4/CD8+ T-cell ratio [1]. Although diarrhea is the main gastrointestinal manifestation of the syndrome, in most cases no definite pathogens are identified [2]. A lack of plasma cells in the lamina propria, epithelial apoptosis, and increased IELs are characteristic histopathological findings in common variable immunodeficiency, a primary immunodeficiency similar to Good syndrome [3] [4], but not in Good syndrome. This is the first report in English describing endoscopic and pathological improvement of refractory gastrointestinal ulcers in Good syndrome by IVIG treatment. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC
- 10 February 2012
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 44 (S 02) , E246-E247
Open AccessA case of Good syndrome with refractory gastrointestinal ulcers
A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication). On the patient’s admission, laboratory examination revealed severe hypogammaglobulinemia, absence of peripheral B cells, CD4+ T-cell lymphopenia, and inverted CD4 /CD8+ T-cell ratio. Pathogenic bacteria, cytomegalovirus, and human immunodeficiency virus tests were negative. From these results and her medical history, the patient was diagnosed with Good syndrome with PRCA, and was treated with intravenous immune globulin (IVIG) every 2 weeks. At 2 months later, her immune globulin level had increased to normal. Previously upper and lower gastrointestinal endoscopy had shown an ulcer at the greater curvature ([Fig. 1 a]), and similar multiple ulcers at the ileocecum and the terminal ileum on admission ([Fig. 1 c]). Histopathological analysis of the biopsy specimens from these lesions showed a lack of plasma cells in the lamina propria, epithelial apoptosis, and increased intraepithelial lymphocytes (IELs) ([Fig. 2]). Similarly, 2 months after initiation of IVIG treatment, these lesions were markedly improved ([Fig. 1 b, d]), and the epithelial apoptosis and IELs had disappeared. Good syndrome is defined as thymoma with adult-onset immunodeficiency, and is characterized by hypogammaglobulinemia, low or absent B-cells, CD4+ T-cell lymphopenia, and inverted CD4/CD8+ T-cell ratio [1]. Although diarrhea is the main gastrointestinal manifestation of the syndrome, in most cases no definite pathogens are identified [2]. A lack of plasma cells in the lamina propria, epithelial apoptosis, and increased IELs are characteristic histopathological findings in common variable immunodeficiency, a primary immunodeficiency similar to Good syndrome [3] [4], but not in Good syndrome. This is the first report in English describing endoscopic and pathological improvement of refractory gastrointestinal ulcers in Good syndrome by IVIG treatment. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC
- Open Access
- 1 January 2012
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 51 (3) , 216-220
Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms
Gastrointestinal symptoms are a problematic issue for patients who take low-dose aspirin for long time. We conducted a pilot study to investigate the efficacy of combination therapy with proton pump inhibitor and rebamipide. This was a prospective, randomized, double-blind, placebo-controlled cross-over study. All the subjects received aspirin 100 mg and omeprazole 20 mg. The subjects were divided into two groups and received either rebamipide 300 mg or placebo, which was prescribed for 4 weeks. The subjects were instructed to record their gastrointestinal symptom rating scale before the study and 1 and 4 weeks after beginning the protocol. These scores of the groups were compared before and after the treatment to evaluate the severity of their symptoms and the number of symptom items present in each group. For the subjects receiving rebamipide, the total prevalence of lower gastrointestinal symptoms was significantly different from the placebo group (p=0.0093) at week 4. No troublesome symptoms were observed in the rebamipide group. Inconclusion, the administration of rebamipide prevented the occurrence of troublesome symptoms, especially lower gastrointestinal symptoms, in patients taking aspirin and omeprazole. Rebamipide is a candidate drug for combination therapy with proton pump inhibitors to prevent low-dose aspirin-induced gastrointestinal symptoms.
- 1 January 2012
- Published by The Society for Free Radical Research Japan in Journal of Clinical Biochemistry and Nutrition
- Vol. 51 (3) , 216-220
Open AccessEfficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms
Gastrointestinal symptoms are a problematic issue for patients who take low-dose aspirin for long time. We conducted a pilot study to investigate the efficacy of combination therapy with proton pump inhibitor and rebamipide. This was a prospective, randomized, double-blind, placebo-controlled cross-over study. All the subjects received aspirin 100 mg and omeprazole 20 mg. The subjects were divided into two groups and received either rebamipide 300 mg or placebo, which was prescribed for 4 weeks. The subjects were instructed to record their gastrointestinal symptom rating scale before the study and 1 and 4 weeks after beginning the protocol. These scores of the groups were compared before and after the treatment to evaluate the severity of their symptoms and the number of symptom items present in each group. For the subjects receiving rebamipide, the total prevalence of lower gastrointestinal symptoms was significantly different from the placebo group (p=0.0093) at week 4. No troublesome symptoms were observed in the rebamipide group. Inconclusion, the administration of rebamipide prevented the occurrence of troublesome symptoms, especially lower gastrointestinal symptoms, in patients taking aspirin and omeprazole. Rebamipide is a candidate drug for combination therapy with proton pump inhibitors to prevent low-dose aspirin-induced gastrointestinal symptoms.